Treatment with Endeavor Biomedicines’ experimental oral therapy ENV-101 (taladegib) improved lung function in people with IPF ...

This Veterans Day, columnist Samuel Kirton writes about the PACT Act, which expanded coverage for veterans exposed to toxic substances.

A Phase 2 trial testing experimental therapy CAL101 in people with IPF is recruiting participants. CAL101 has been granted ...

Columnist Samuel Kirton has nothing but praise for caregivers, who represent the best of what is right in the world.

Blocking caspase-9, an enzyme involved in cell death, may be a potential treatment target for pulmonary fibrosis, a ...

The U.S. Food and Drug Administration (FDA) has approved nerandomilast, an oral medication developed by Boehringer Ingelheim, to treat adults with idiopathic pulmonary fibrosis (IPF) — when the lung ...

GRI-0621, an experimental oral therapy for idiopathic pulmonary fibrosis (IPF), may stabilize lung function, according to an interim analysis of an ongoing Phase 2a study. “The FVC data after 6 weeks ...

Second in a series. Read part 1 about the foundation’s work of the past 25 years. During my interview with Scott Staszak, president and CEO of the Pulmonary Fibrosis Foundation (PFF), I was struck by ...

The inhalation therapy Tyvaso (treprostinil) significantly improved a measure of lung function for people with idiopathic pulmonary fibrosis (IPF) in a Phase 3 clinical trial. The top-line result ...

When I talk to patients, caregivers, or family members, almost all of them can recall the details of the pertinent diagnosis. After all, it’s a monumental life event. What each of us hears and how ...

An experimental oral therapy for idiopathic pulmonary fibrosis (IPF) has been tolerated well in an ongoing Phase 2 clinical trial, according to interim data announced by its developer GRI Bio. “We are ...